Fredrik Schjesvold
- Hematology top 1%
- Oncology top 5%
- Molecular Biology top 10%
- Immunology top 10%
- Genetics top 10%
- Co-authors
- Meletios Α. DimopoulosPhilippe MoreauJesús F. San MiguelMichèle CavoPieter SonneveldRoman HájekEvangelos TerposSonja Zweegman
- Topics
- Multiple Myeloma Research and Treatments (86 papers)Protein Degradation and Inhibitors (40 papers)Peptidase Inhibition and Analysis (28 papers)
- Cited by
- HematologyOncologyGenetics
- Journals
- Journal of Clinical OncologySHILAP Revista de lepidopterologíaBlood
- Partner nations
- NorwaySpainUnited States
In The Last Decade
Fredrik Schjesvold
88 papers receiving 1.4k citations
Hit Papers
Peers
Comparison fields: 5 of 91
- Hematology 1.0k
- Oncology 809
- Molecular Biology 766
- Immunology 230
- Genetics 121
Countries citing papers authored by Fredrik Schjesvold
This map shows the geographic impact of Fredrik Schjesvold's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fredrik Schjesvold with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fredrik Schjesvold more than expected).
Fields of papers citing papers by Fredrik Schjesvold
This network shows the impact of papers produced by Fredrik Schjesvold. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fredrik Schjesvold. The network helps show where Fredrik Schjesvold may publish in the future.
Co-authorship network of co-authors of Fredrik Schjesvold
This figure shows the co-authorship network connecting the top 25 collaborators of Fredrik Schjesvold. A scholar is included among the top collaborators of Fredrik Schjesvold based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fredrik Schjesvold. Fredrik Schjesvold is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 1 | |
| 3 | 1 | |
| 4 | 0 | |
| 5 | 0 | |
| 6 | 9 | |
| 7 | 4 | |
| 8 | 1 | |
| 9 | 1 | |
| 10 | 1 | |
| 11 | 2 | |
| 12 | 3 | |
| 13 | 12 | |
| 14 | 5 | |
| 15 | 16 | |
| 16 | 14 | |
| 17 | 1 | |
| 18 | Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†breakdown → | 460 |
| 19 | 4 | |
| 20 | Ixazomib-Thalidomide-Low Dose Dexamethasone (ITd) Induction Followed By Maintenance Therapy with Ixazomib or Placebo in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem Cell Transplantation; Initial Results from the Randomized Phase II HOVON-126/Nmsg 21.13 Trial | 0 |
About Fredrik Schjesvold
Fredrik Schjesvold is a scholar working on Hematology, Oncology and Molecular Biology, having authored 103 papers that have together received 1.4k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (86 papers), Protein Degradation and Inhibitors (40 papers) and Peptidase Inhibition and Analysis (28 papers). The work is most often cited by research in Hematology (1.0k citations), Oncology (809 citations) and Genetics (121 citations). Fredrik Schjesvold has collaborated with scholars based in Norway, Spain and United States. Frequent co-authors include Meletios Α. Dimopoulos, Philippe Moreau, Jesús F. San Miguel, Michèle Cavo, Pieter Sonneveld, Roman Hájek, Evangelos Terpos, Sonja Zweegman, María‐Victoria Mateos and Thierry Façon. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.